VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and ...
Please provide your email address to receive an email when new articles are posted on . The approval applies to certain patients with myasthenia gravis or chronic inflammatory demyelinating ...
SAN DIEGO, April 10, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART ® Hytrulo ...
Please provide your email address to receive an email when new articles are posted on . Psoriasis patients who self-administer bimekizumab experienced similar levels of comfort and success with both ...
Many people living with rheumatoid arthritis (RA) rely on long-term medications to manage joint pain, stiffness, and inflammation. A number of these treatments are given as subcutaneous injections, ...
The global prefilled syringes market is forecasted to grow from USD 8.65 billion in 2026 to USD 14.53 billion by 2031, at a CAGR of 10.9%. Key growth drivers include the rising prevalence of chronic ...
HYDERABAD, India, March 16, 2026 /PRNewswire/ -- According to Mordor Intelligence, the global prefilled syringes market is experiencing strong expansion as healthcare systems increasingly prioritize ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results